Granules India Limited has formally communicated to the National Stock Exchange of India regarding its classification status under SEBI regulations. The pharmaceutical company has confirmed that it does not meet the criteria for Large Corporate classification as outlined in the regulatory framework.

Regulatory Classification Status

The company has officially stated that it does not fall under the Large Corporate category as per the criteria specified in SEBI circular no. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. This notification serves as a formal compliance measure to keep the exchange informed about the company's current regulatory status.

Compliance Commitment

Granules India Limited has provided a formal undertaking to the National Stock Exchange, committing to inform the exchange as and when the company becomes a Large Corporate as per the aforementioned SEBI circular. This proactive approach ensures ongoing regulatory compliance and transparency with market regulators.

The undertaking was digitally signed by Chaitanya Tummala, who serves as the Company Secretary and Compliance Officer for Granules India Limited. The digital signature was executed on April 8, 2026, at 15:07:49 +05'30', providing a timestamped record of the formal communication.

Company Information

Granules India Limited operates from its registered office located at the 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India. The company holds CIN: L24110TG1991PLC012471 and maintains its corporate communications through established channels including telephone, fax, and email services.

Granules India has successfully completed a US FDA Current Good Manufacturing Practice (CGMP) audit at its Chantilly manufacturing facility. The regulatory inspection, conducted from March 30 to April 3, 2026, concluded with the pharmaceutical company receiving four Form 483 observations from the FDA.

FDA Audit Results

The audit results present a mixed but manageable regulatory outcome for Granules India. While the company received four Form 483 observations, significantly, no data integrity issues were reported during the inspection. This absence of data integrity concerns is particularly noteworthy, as such issues typically represent more serious regulatory violations that can impact manufacturing operations and product approvals.

Regulatory Compliance Status

Form 483 observations are issued by the FDA when inspectors identify conditions or practices that may violate FDA regulations. The observations received are related to procedural matters, and the fact that Granules India received only four observations without any data integrity issues suggests that the facility maintains acceptable manufacturing standards. This marks the second US FDA inspection at the Chantilly facility in the last one year.

Manufacturing Operations Impact

The completion of the FDA audit represents an important regulatory milestone for Granules India's Chantilly facility. The absence of data integrity issues indicates that the company's quality systems and documentation practices at the site meet FDA expectations. Granules remains committed to maintaining the highest standards of quality, safety, and regulatory compliance and will address the observations raised by the US FDA within the stipulated timelines.

The Chantilly facility is operated by Granules Pharmaceuticals, Inc., a wholly-owned subsidiary of Granules India Limited. This regulatory clearance supports the facility's continued operations and its ability to supply products to the US market.